| DC21171 |
JNJ-10198409 |
JNJ-10198409 is a highly potent, selective PDGFRβ inhibitor with IC50 of 4.2 nM. |
|
| DC23504 |
JNJ16567083 |
JNJ16567083 (EMQMCM) is a potent and selective mGluR1 antagonist that shows neuroprotective effects in some hypoxia-ischemia models. |
|
| DC7617 |
JNJ-1661010 |
JNJ-1661010 is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2. |
|
| DC22665 |
JNJ18038683
Featured
|
JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays. |
|
| DC22717 |
JNJ-18038683 free base |
JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays. |
|
| DC21910 |
JNJ-1A |
JNJ-1A is a novel Dengue virus (DENV) NS4B inhibitor that inhibits DENV-2 sub-genomic replicon at 0.7 μM, in the absence of cytotoxicity. |
|
| DC11115 |
JNJ-26489112 |
JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. |
|
| DC21172 |
JNJ-26993135 |
JNJ-26993135 is a potent, selective leukotriene A4 hydrolase (LTA4H) inhibitor, inhibits both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA4H with IC50 of 10 nM. |
|
| DC22716 |
JNJ-28307474 |
JNJ-28307474 is a potent, selective antagonist of the histamine H4 receptor (H4R), inhibits LPS-induced TNF production.. |
|
| DC21173 |
JNJ-28312141 hydrochloride |
JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM. |
|
| DC22689 |
JNJ-28610244 |
JNJ-28610244 is a potent, selective agonist of histamine H4 receptor (H4R).. |
|
| DC23567 |
JNJ303
Featured
|
JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents). |
|
| DC22405 |
JNJ-37822681 |
JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM. |
|
| DC21440 |
JNJ-38877618 |
JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. |
|
| DC21174 |
JNJ-38893777 |
JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.. |
|
| DC21175 |
JNJ-38893777 sulfate |
JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.. |
|
| DC22738 |
JNJ-39393406 |
JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM. |
|
| DC21176 |
JNJ-39729209 |
JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively. |
|
| DC22750 |
JNJ-39933673 hemihydrate |
JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor.. |
|
| DC22751 |
JNJ-39933673 |
JNJ-39933673 is a potent, selective SGLT2 inhibitor.. |
|
| DC22683 |
JNJ-40279486 |
JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation.. |
|
| DC21178 |
JNJ-40413269 |
JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively. |
|
| DC22757 |
JNJ-42314415 |
JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A. |
|
| DC21169 |
JNJ-42905343 |
JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively. |
|
| DC22125 |
JNJ4796
Featured
|
JNJ4796 (JNJ 4796, JNJ-4796) is an orally active small-molecule fusion inhibitor of influenza virus hemagglutinin (HA) with EC50 of 33 nM (H1N1 neutralization). |
|
| DC21180 |
JNJ-47965567
Featured
|
JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively. |
|
| DC21597 |
JNJ-49095397 |
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively. |
|
| DC23679 |
JNJ-4929821 |
JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM.. |
|
| DC21181 |
JNJ-5234801 |
JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety.. |
|
| DC21170 |
JNJ525
Featured
|
JNJ525 is a small molecule inhibitor that targets tumor necrosis factor alpha (TNFα), a cytokine involved in inflammation and immune regulation. TNFα exerts its biological effects by binding to its receptors, TNFR1 (TNF receptor 1) and TNFR2 (TNF receptor 2). JNJ525 works by preventing the formation of TNFα complexes with these receptors, thereby inhibiting TNFα-mediated signaling pathways. |
|
